利培酮与氯氮平治疗精神分裂症的对照研究

A controlled trial of risperidone versus clozapine in the treatment of schizophrenia

６０例ＰＡＮＳＳ总分≥６０，符合ＤＳＭ—Ⅳ精神分裂症诊断标准的患者，分别给予利培酮或氯氮平治疗。经８周随机对照研究发现，ＰＡＮＳＳ、ＣＧＩ、ＥＳＲＳ、ＴＥＳＳ量表评定显示，利培酮治疗精神分裂症疗效肯定，有效率９６．７％，与氯氮平相仿。利培酮在治疗１周后起效，阴性症状见效尤早，剂量较小者锥体外系副反应轻，其他不良反应发生率和严重程度较氯氮平明显少而轻，治疗的依从性与生活质量较高。本研究证实。

Objective:To compare the efficacy and side effects between risperidone and clozapine in the treatment of schizophrenia. Method:60 inpatients with diagnosis of schizophrenia according to DSM-IV and PANSS score≥60 were treated with either risperidone or clozapine in a double blind trial.PANSS,CGI,ESRS and TESS were used to monitor the therapeutic response and side effects. Results:967% of patients showed definite response to risperidone which is comparable to clozapine.The onset of action was about one week and slightly earlier for negative symptoms.There were less extra-pyramidal side effects especially with low dose.As compared to clozapine,there were fewer side effects in general.There was also better drug compliance with superior quality of life. Discussion:Risperidone was a safe and effective treatment for schizophrenia.